Recently, the negative prognostic impact of coexpression of MYC and BCL2 has been confirmed in DLBCL patients from Western populations treated with R-CHOP [16], [23], [28], [29]. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.